Research

Small molecule drugs have been the mainstay of the pharmaceutical industry for nearly a century. Defined as any organic compound with low molecular weight, small molecule drugs have some distinct advantages as therapeutics: most can be administered orally and they can pass through cell membranes to reach intracellular targets.

Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient cohort which showed a 22% reduction in the risk of death versus chemotherapy alone.

The PACIFIC-2 Phase III trial for Imfinzi (durvalumab) concurrently administered with chemoradiotherapy (CRT) did not achieve statistical significance for the primary endpoint of progression-free survival (PFS) versus CRT alone for the treatment of patients with unresectable, Stage III non-small cell lung cancer (NSCLC).

L'obiettivo di questo progetto è quello di identificare le principali sottopopolazioni cellulari che vengono modificate dopo l'infezione da HIV-1, predirne e modificarne le loro interazioni.

Studio dei meccanismi molecolari mediante i quali le cellule neuronali rispondono a stress neurodegenerativi modulando l'interazione tra mitocondri e nucleo e caratterizzazione del ruolo della autofagia in questa modulazione.

First global Phase III trial to show improved clinical outcome for systemic therapy in combination with transarterial chemoembolisation (TACE) in this setting.